Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC By Ogkologos - July 9, 2025 825 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus... February 24, 2025 Discover and translate – a mantra to work by October 17, 2022 COVID Vaccine Basics for Cancer Patients January 18, 2021 p53 Mutations May Differentially Affect Survival of Patients with mCRC Based... December 3, 2021 Load more HOT NEWS Adjuvant Pembrolizumab Prolongs DFS Among Patients with High-Risk Muscle Invasive Urothelial... Young Mom Battles Breast Cancer After Being Misdiagnosed with a Blocked... FDA Grants Regular Approval to Dostarlimab-gxly for dMMR Endometrial Cancer First New Drug in Years Reduces Recurrence in High-risk Hormone Receptor...
